Among patients with metastatic castration-sensitive prostate cancer, apalutamide plus ADT improves OS with a significant reduction in risk of death.
Patients with prostate cancer who were non-adherent to advanced oral therapies experienced substantially higher HCRU than those who were adherent.
Apalutamide Plus Abiraterone Extends Radiographic PFS in Metastatic Castration-Resistant Prostate Cancer
Apalutamide added to abiraterone acetate plus prednisone improves radiographic PFS by 7.4 months vs abiraterone acetate plus prednisone alone in metastatic castration-resistant prostate cancer.
Findings from a real-world study show abiraterone is associated with greater risk of cardiovascular-related hospitalizations among men with prostate cancer than enzalutamide.